SCHEMBL6846960

SCHEMBL6846960

O=C(CCCc1ccc(Cl)cc1)NCCC1CCCc2[nH]cnc21

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 2/20 0.42
POLB P06746 2/20 0.40
MAPT P10636 1/20 0.40
ALDH1A1 P00352 4/20 0.38
KMT2A Q03164 2/20 0.38
HDAC3 O15379 1/20 0.38
HDAC4 P56524 1/20 0.38
HDAC1 Q13547 1/20 0.38
HDAC7 Q8WUI4 1/20 0.38
HDAC2 Q92769 1/20 0.38
HDAC10 Q969S8 1/20 0.38
HDAC11 Q96DB2 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
HDAC6 Q9UBN7 1/20 0.38
HDAC9 Q9UKV0 1/20 0.38
HDAC5 Q9UQL6 1/20 0.38
ATM Q13315 1/20 0.38
MEN1 O00255 1/20 0.38
L3MBTL1 Q9Y468 2/20 0.36
HSD17B10 Q99714 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6849675 0.90 ALDH1A1 (0.41) HRH3POLBMAPTALDH1A1KMT2A
SCHEMBL6853121 0.88 SMN1; SMN2 (0.43) POLBALDH1A1KMT2AMEN1TP53
SCHEMBL6851398 0.84 KMT2A (0.40) ALDH1A1KMT2AHDAC1HDAC6ATM
SCHEMBL6847114 0.82 L3MBTL1 (0.42) ALDH1A1KMT2AMEN1L3MBTL1TSHR
SCHEMBL7654772 0.81 ALDH1A1 (0.38) ALDH1A1TSHRTP53HPGDLMNA
SCHEMBL6849634 0.78 POLB (0.43) POLBALDH1A1KMT2AMEN1LMNA
SCHEMBL7141811 0.77 NPC1 (0.39) ALDH1A1KMT2AMEN1L3MBTL1HPGD
SCHEMBL6850901 0.75 CCNA2 (0.42) MAPTALDH1A1KMT2AHDAC3HDAC4
SCHEMBL6846803 0.73 CCR2 (0.41) HRH3POLBMAPTALDH1A1HDAC3
SCHEMBL6846909 0.70 LMNA (0.45) POLBHDAC3HDAC4HDAC1HDAC7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6756384-B2 TREATMENT OF DISEASES AND DISORDERS RELATED TO THE HISTAMINE H3 RECEPTOR. NOVO NORDISK A/S (DK) 2004-06-29 US disclosed
US-20030135056-A1 Imidazole compounds HIGH POINT PHARMACEUTICALS, LLC 2003-07-17 US disclosed
EP-1268484-A1 CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS NOVO NORDISK A/S (DK) 2003-01-02 EP disclosed
US-6437147-B1 FOR THERAPY OF DISEASES OF CENTRAL NERVOUS SYSTEM, PERIPHERAL NERVOUS SYSTEM, CARDIOVASCULAR SYSTEM, PULMONARY SYSTEM, GASTROINTESTINAL SYSTEM AND ENDOCRINOLOGICAL SYSTEM NOVO NORDISK (DK) 2002-08-20 US disclosed
US-20020058659-A1 Imidazole compounds HIGH POINT PHARMACEUTICALS, LLC 2002-05-16 US disclosed
WO-2001068652-A1 CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS NOVO NORDISK A/S (DK) 2001-09-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030135056-A1 Imidazole compounds HRH3, HRH4, HRH2 HRH3 1/4885POLB 4423/4885MAPT 1175/4885
US-20020058659-A1 Imidazole compounds HRH3, HRH4, HRH2 HRH3 1/4885POLB 4423/4885MAPT 1175/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.